NR 565 FINAL EXAM – ADVANCED
PHARMACOLOGY
(2026/2027 Edition)
Walden University • Advanced Practice Pharmacology
100 Questions • Comprehensive Final Examination
Format: 100 multiple-choice questions (single best answer, A–D).
Structure: Eight sections spanning the full advanced pharmacology curriculum.
Cognitive ~30% recall • ~50% application • ~20% analysis.
levels:
Grading: One point per question; correct answer and rationale provided after each
item.
Content basis: Current FDA/CDC guidance and evidence-based prescribing standards for
the 2026/2027 academic year.
Special 5 items on 2026/2027 FDA label changes & new indications; 3
inclusions: pharmacogenomic items (CYP2D6, CYP2C19, HLA-B); 2 comprehensive
5-step prescribing cases.
, Section 1: Pharmacokinetics, Pharmacodynamics, & Pharmacogenomics (15
questions)
Q1: A 62-year-old patient with cirrhosis takes propranolol 40 mg twice daily for portal hypertension.
Because of reduced hepatic extraction and impaired first-pass metabolism, the provider anticipates
which pharmacokinetic change?
A. Increased systemic bioavailability and risk of accumulation [CORRECT]
B. Increased clearance and shorter half-life
C. Decreased bioavailability and need for higher dose
D. No change in metabolism because propranolol is renally cleared
Correct Answer: A
Rationale: C is correct: propranolol is a high-extraction drug that undergoes extensive first-pass hepatic
metabolism; cirrhosis reduces this, raising systemic bioavailability and risk of accumulation. A, B, and D are
incorrect because first-pass loss is reduced (not increased), doses usually need reduction, and propranolol is
hepatically, not renally, cleared.
Q2: A 70-year-old man with CKD stage 4 (eGFR 28 mL/min/1.73 m²) needs treatment for a urinary
tract infection. Which antibiotic requires dose reduction or avoidance at this level of renal
impairment?
A. Cephalexin
B. Nitrofurantoin [CORRECT]
C. Doxycycline
D. Ceftriaxone
Correct Answer: B
Rationale: A is correct: nitrofurantoin is ineffective and contraindicated when eGFR <30 because it does not
reach the urinary tract in therapeutic concentrations and may accumulate. B, C, and D are wrong because
cephalexin and ceftriaxone can be used (with adjustment if needed), and doxycycline is hepatically cleared
and safe in CKD.
Q3: Which CYP450 enzyme is responsible for the metabolism of the majority of currently prescribed
medications and is a common target of drug interactions?
A. CYP1A2
B. CYP2D6
C. CYP3A4 [CORRECT]
D. CYP2C9
Correct Answer: C
Rationale: C is correct: CYP3A4 metabolizes roughly 40-50% of marketed drugs and is a major site of
induction/inhibition interactions. A, B, and D are important enzymes but metabolize a smaller fraction of drugs
than CYP3A4.
NR 565 – Advanced Pharmacology (2026/2027 Edition) Page 2
, Q4: A patient with major depressive disorder has a CYP2D6 genotype consistent with a poor
metabolizer phenotype. She is prescribed a drug that is an active CYP2D6 prodrug requiring
metabolic activation to its active metabolite. Which outcome is most expected?
A. Enhanced efficacy and higher active metabolite levels
B. Increased risk of toxicity from the parent drug
C. No change because prodrug activation is CYP-independent
D. Reduced conversion to the active metabolite and potential therapeutic failure [CORRECT]
Correct Answer: D
Rationale: B is correct: in a poor metabolizer, an inactive CYP2D6 prodrug is poorly converted to its active
form, risking therapeutic failure. A is wrong because metabolism is reduced; C is wrong because
accumulation of an inactive parent does not produce pharmacologic toxicity; D is wrong because activation is
enzyme-dependent.
Q5: A drug has a half-life of 24 hours. Approximately how long will it take to reach steady state if the
patient is loaded at the maintenance dose without a loading dose?
A. 5 half-lives (about 5 days) [CORRECT]
B. 24 hours
C. 2-3 days
D. 10 half-lives (about 10 days)
Correct Answer: A
Rationale: C is correct: steady state is reached in about 4-5 half-lives, so ~5 days for a 24-hour half-life. A
and B underestimate steady state; D overestimates it (beyond 5 half-lives there is negligible further change).
Q6: Which of the following medications would most likely require dose reduction in a patient with
moderate-to-severe hepatic impairment?
A. Warfarin
B. Morphine [CORRECT]
C. Metformin
D. Doxycycline
Correct Answer: B
Rationale: B is correct: morphine undergoes extensive hepatic glucuronidation and can accumulate in
hepatic impairment, increasing sedation and respiratory depression risk. A (warfarin) requires careful
monitoring more than a strict dose reduction rule; C and D are predominantly cleared by renal/other routes
and are safer in hepatic dysfunction.
Q7: A patient is a CYP2C19 poor metabolizer and requires dual antiplatelet therapy after stent
placement. Which statement is most accurate regarding clopidogrel?
A. Clopidogrel is fully effective regardless of CYP2C19 status
B. Poor metabolizers have increased bleeding risk with clopidogrel
C. Clopidogrel requires CYP2C19 activation; poor metabolizers may have reduced antiplatelet
effect [CORRECT]
D. Clopidogrel should be dose-doubled safely in all patients
Correct Answer: C
Rationale: B is correct: clopidogrel is a prodrug activated by CYP2C19; poor metabolizers convert less to the
active metabolite, reducing platelet inhibition. A is false; C is false (poor metabolizers have reduced effect,
not increased bleeding); D is not a uniform safe strategy.
NR 565 – Advanced Pharmacology (2026/2027 Edition) Page 3
PHARMACOLOGY
(2026/2027 Edition)
Walden University • Advanced Practice Pharmacology
100 Questions • Comprehensive Final Examination
Format: 100 multiple-choice questions (single best answer, A–D).
Structure: Eight sections spanning the full advanced pharmacology curriculum.
Cognitive ~30% recall • ~50% application • ~20% analysis.
levels:
Grading: One point per question; correct answer and rationale provided after each
item.
Content basis: Current FDA/CDC guidance and evidence-based prescribing standards for
the 2026/2027 academic year.
Special 5 items on 2026/2027 FDA label changes & new indications; 3
inclusions: pharmacogenomic items (CYP2D6, CYP2C19, HLA-B); 2 comprehensive
5-step prescribing cases.
, Section 1: Pharmacokinetics, Pharmacodynamics, & Pharmacogenomics (15
questions)
Q1: A 62-year-old patient with cirrhosis takes propranolol 40 mg twice daily for portal hypertension.
Because of reduced hepatic extraction and impaired first-pass metabolism, the provider anticipates
which pharmacokinetic change?
A. Increased systemic bioavailability and risk of accumulation [CORRECT]
B. Increased clearance and shorter half-life
C. Decreased bioavailability and need for higher dose
D. No change in metabolism because propranolol is renally cleared
Correct Answer: A
Rationale: C is correct: propranolol is a high-extraction drug that undergoes extensive first-pass hepatic
metabolism; cirrhosis reduces this, raising systemic bioavailability and risk of accumulation. A, B, and D are
incorrect because first-pass loss is reduced (not increased), doses usually need reduction, and propranolol is
hepatically, not renally, cleared.
Q2: A 70-year-old man with CKD stage 4 (eGFR 28 mL/min/1.73 m²) needs treatment for a urinary
tract infection. Which antibiotic requires dose reduction or avoidance at this level of renal
impairment?
A. Cephalexin
B. Nitrofurantoin [CORRECT]
C. Doxycycline
D. Ceftriaxone
Correct Answer: B
Rationale: A is correct: nitrofurantoin is ineffective and contraindicated when eGFR <30 because it does not
reach the urinary tract in therapeutic concentrations and may accumulate. B, C, and D are wrong because
cephalexin and ceftriaxone can be used (with adjustment if needed), and doxycycline is hepatically cleared
and safe in CKD.
Q3: Which CYP450 enzyme is responsible for the metabolism of the majority of currently prescribed
medications and is a common target of drug interactions?
A. CYP1A2
B. CYP2D6
C. CYP3A4 [CORRECT]
D. CYP2C9
Correct Answer: C
Rationale: C is correct: CYP3A4 metabolizes roughly 40-50% of marketed drugs and is a major site of
induction/inhibition interactions. A, B, and D are important enzymes but metabolize a smaller fraction of drugs
than CYP3A4.
NR 565 – Advanced Pharmacology (2026/2027 Edition) Page 2
, Q4: A patient with major depressive disorder has a CYP2D6 genotype consistent with a poor
metabolizer phenotype. She is prescribed a drug that is an active CYP2D6 prodrug requiring
metabolic activation to its active metabolite. Which outcome is most expected?
A. Enhanced efficacy and higher active metabolite levels
B. Increased risk of toxicity from the parent drug
C. No change because prodrug activation is CYP-independent
D. Reduced conversion to the active metabolite and potential therapeutic failure [CORRECT]
Correct Answer: D
Rationale: B is correct: in a poor metabolizer, an inactive CYP2D6 prodrug is poorly converted to its active
form, risking therapeutic failure. A is wrong because metabolism is reduced; C is wrong because
accumulation of an inactive parent does not produce pharmacologic toxicity; D is wrong because activation is
enzyme-dependent.
Q5: A drug has a half-life of 24 hours. Approximately how long will it take to reach steady state if the
patient is loaded at the maintenance dose without a loading dose?
A. 5 half-lives (about 5 days) [CORRECT]
B. 24 hours
C. 2-3 days
D. 10 half-lives (about 10 days)
Correct Answer: A
Rationale: C is correct: steady state is reached in about 4-5 half-lives, so ~5 days for a 24-hour half-life. A
and B underestimate steady state; D overestimates it (beyond 5 half-lives there is negligible further change).
Q6: Which of the following medications would most likely require dose reduction in a patient with
moderate-to-severe hepatic impairment?
A. Warfarin
B. Morphine [CORRECT]
C. Metformin
D. Doxycycline
Correct Answer: B
Rationale: B is correct: morphine undergoes extensive hepatic glucuronidation and can accumulate in
hepatic impairment, increasing sedation and respiratory depression risk. A (warfarin) requires careful
monitoring more than a strict dose reduction rule; C and D are predominantly cleared by renal/other routes
and are safer in hepatic dysfunction.
Q7: A patient is a CYP2C19 poor metabolizer and requires dual antiplatelet therapy after stent
placement. Which statement is most accurate regarding clopidogrel?
A. Clopidogrel is fully effective regardless of CYP2C19 status
B. Poor metabolizers have increased bleeding risk with clopidogrel
C. Clopidogrel requires CYP2C19 activation; poor metabolizers may have reduced antiplatelet
effect [CORRECT]
D. Clopidogrel should be dose-doubled safely in all patients
Correct Answer: C
Rationale: B is correct: clopidogrel is a prodrug activated by CYP2C19; poor metabolizers convert less to the
active metabolite, reducing platelet inhibition. A is false; C is false (poor metabolizers have reduced effect,
not increased bleeding); D is not a uniform safe strategy.
NR 565 – Advanced Pharmacology (2026/2027 Edition) Page 3
